Early-stage breast cancer treatment: given the complex nature of the disease, the ability to clearly explain the therapeutic options available to patients with breast cancer is invaluable.Kentley, Donna
In Stage 1 breast cancer, thecanceris still considered in an early stage. Learn about its treatment options. Stage 1 Breast Cancer Treatment Options Not Sure How to Start the Conversation About Early Breast Cancer Treatment? A 17-year breast cancer survivor walks you through how to prepare for...
There’s no one-size-fits-all approach, but early-stage breast cancer is very treatable. Your doctor will consider things like type, stage, and lifestyle.
Treatment of Early-Stage Breast Cancer.Focuses on the issues concerning the treatment of first-stage breast cancer that were discussed during a convention held by the National Cancer Institute and the U.S. National Institute of Health Office of Medical Applications of Research on June 18-21, ...
Dr Sardesai on Lasofoxifene Plus Abemaciclib in ESR1-Mutant, ER+/HER2– Breast Cancer Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL): DESTINY-Breast12 (DB-12) results Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer ...
Surgery is considered primary treatment for early-stage breast cancer; many patients are cured with surgery alone. The goals of breast cancer surgery include complete resection of the primary tumor with negative margins to reduce the risk of local recurrences and pathologic staging of the tumor and...
1. Sharma P: Optimal systemic therapy for early-stage triple-negative breast cancer. Invited Lecture. 2023 Miami Breast Cancer Conference. Presented March 3, 2023. 2. Loibl S et al: Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy ...
2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series(《HER2低表达状态在早期浸润...
Expert medical oncologists provide an overview of current endocrine therapy approved for early-stage breast cancer.
William J. Gradishar, MD, highlights the inclusion of abemaciclib in the NCCN Guidelines for select high-risk early-stage breast cancer patients, anticipates the potential for ribociclib to secure a similar guideline position, and emphasizes the importan